Navigation Links
Thrombosis Experts Present Update on Important New Developments in Anticoagulation Management
Date:10/29/2010

RESEARCH TRIANGLE PARK, N.C., Oct. 29 /PRNewswire/ -- Pharmaceutical Strategic Initiatives® announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.  The symposium titled Anticoagulation Management at the Crossroads –Addressing the Developments Impacting Future Decades was sponsored by Research Triangle Park, NC based Pharmaceutical Strategic Initiatives, LLC.  This interactive symposium was organized in collaboration with the Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, the North American Thrombosis Forum (NATF), and the International Union of Angiology (IUA).

Professor Jawed Fareed, Ph.D., Professor of Pathology and Pharmacology, Director of Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, IL, was the chair for the program which also included presentations regarding emerging topics in anticoagulation management and for patients at risk of thrombosis and related disorders.  The distinguished faculty representing leading international institutions included Professor Samuel Goldhaber, MD from Brigham and Women's Hospital in Boston, MA, Professor Jeanine Walenga, Ph.D. from Loyola University Medical Center in Maywood, IL, Professor Benjamin Brenner from Rambam Health Care Campus in Haifa, Israel, Massimo Iacobelli, M.D. from Gentium, S.P.A. in Como Italy, Professor Selim Corbacioglu, M.D. from Children's Hospital Regensburg in Regensburg, Germany, Ilene Sussman, Ph.D. from the North American Thrombosis Forum in Boston, MA and Charles Carter, Pharm.D. from Pharmaceutical Strategic Initiatives, LLC in Research Triangle Park, NC.  The topics presented and discussed covered new treatment modalities for the prevention and treatment of patients at risk for thrombotic and vascular disorders including atrial fibrillation, acute coronary syndromes, diabetes, cancer and transplantation associated venous occlusive disorder.  In addition, the panel considered recent worldwide regulatory developments that are changing the landscape of anticoagulation therapy which includes the introduction of newer oral anticoagulants and generic versions of branded drugs.  The symposium was very well attended and a number of the hematology professionals who attended expressed their appreciation of this timely and informative session.

Pharmaceutical Strategic Initiatives LLC (PSI) is the premier provider of strategic clinical and regulatory consulting, priority comparative effectiveness and outcomes research, scientific content creation, opinion leader development and management to Academic Institutions, Pharmaceutical, Medical Device and Biotechnology companies. For 26 years, PSI has supported Educational Programs and Workshops, Medical Affairs, Regulatory Affairs, and Medical Marketing teams by developing successful business strategies and providing the implementation skills required to produce clear, measurable outcomes.  Charles A. Carter, Pharm.D., MBA is president of Pharmaceutical Strategic Initiatives, LLC.  PSI's offices are in Research Triangle Park, North Carolina.


'/>"/>
SOURCE Pharmaceutical Strategic Initiatives LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
2. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
3. The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment
4. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
5. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
6. Nanobiotechnology experts join forces to improve TB testing
7. Bait and Switch TV's Free Live Debates Invite TV Viewers to Debate with Experts in Real Time about Controversial Topics
8. Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. What's Next for Stevia? Experts from GLG Life Tech Corp Share Views on Stevia's Future at Complimentary Webinar on 17 Feb.
11. Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):